Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2005
09/15/2005WO2005084679A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
09/15/2005WO2005084649A1 Stable capsule preparation
09/15/2005WO2005084646A1 Powdered compositions of sensitive active materials in an at least partially amorphous state
09/15/2005WO2005084641A1 Method and apparatus for producing carrier complexes
09/15/2005WO2005084638A2 Formulations decreasing infectivity of pulmonary diseases
09/15/2005WO2005084632A1 Method and composition for burned skin
09/15/2005WO2005084581A1 Medical three-dimensional structure, process for producing the same and production apparatus
09/15/2005WO2005084444A1 Compositions and methods for the treatment and clinical remission of psoriasis
09/15/2005WO2005084361A2 Multi-component biological transport systems
09/15/2005WO2005084307A2 Use of lipid conjugates in the treatment of disease
09/15/2005WO2005061552A8 Amphiphilic heparin derivative formed by coupling a heparin with a bile acid
09/15/2005WO2005060361A3 Pharmaceutical formulations for itraconazole
09/15/2005WO2005027966A3 Antibodies with altered effector functions
09/15/2005WO2005023309A3 Design of re-targeted toxin conjugates
09/15/2005WO2005023181B1 Polymeric systems for controlled drug therapy
09/15/2005WO2005020900A3 Delivery of a therapeutic agent in a formulation for reduced toxicity
09/15/2005WO2005016256A3 Hemostatic compositions containing sterile thrombin
09/15/2005WO2005014777A3 Methods and compositions for increasing the efficacy of biologically-active ingredients
09/15/2005WO2005010151A3 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
09/15/2005WO2005001022A3 Methods and compositions for enhancing immune response
09/15/2005WO2005000210A3 Synthesis of high molecular weight iron-saccharidic complexes
09/15/2005WO2004082620A3 Oxycodone conjugates with lower the abuse potential and extended duration of action
09/15/2005WO2004078092A3 Cream dispenser
09/15/2005WO2004047771A3 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
09/15/2005WO2004009112A8 Use of urease for inhibiting cancer cell growth
09/15/2005WO2003095626A3 Purified composition of bispecific molecules and methods of production
09/15/2005US20050204412 Artery- and vein-specific proteins and uses therefor
09/15/2005US20050203289 Functional biopolymer modification reagents and uses thereof
09/15/2005US20050203186 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/15/2005US20050203175 Ethanol, Glycerol formal, Water, Methyl-parahydroxy benzoate and Propyl-parahydroxy benzoate; analgesic, antipyretic, antiinflammatory
09/15/2005US20050203166 Indole-3-acetic acid derivatives
09/15/2005US20050203055 Administering an effective amount of a sulfated polysaccharide for therapy and prophylaxis of fungal infection
09/15/2005US20050203040 siNA molecule comprising a double-stranded structure that down-regulates expression of vascular cell adhesion molecule (VCAM), wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference
09/15/2005US20050203020 Safe drug administration carrier capable of extending the half life of a drug in the blood without the risk of contamination of viruses
09/15/2005US20050203017 For activating the non-proteolytically activated thrombin receptor
09/15/2005US20050203016 Method of drug delivery through selective targeting, of biological tissues containing populations of receptor proteins, with novel conjugate molecules
09/15/2005US20050203004 Pharmacologically active polypeptide glycoconjugates
09/15/2005US20050203000 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
09/15/2005US20050202538 Fc-erythropoietin fusion protein with improved pharmacokinetics
09/15/2005US20050202491 Mixture comprising corrosion-inhibiting, wetting, solubilizing and nucleic acid deactivating agents for use as tool in transcription-based amplification assays
09/15/2005US20050202091 Stable pharmaceutical composition comprising erythropoietin
09/15/2005US20050202090 Novel pharmaceutical dosage forms and method for producing same
09/15/2005US20050202089 Sustained-release pharmaceutical formulations containing mizolastine
09/15/2005US20050202088 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof
09/15/2005US20050202076 Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes
09/15/2005US20050202072 Dry mouldable drug formulation
09/15/2005US20050202063 Food product
09/15/2005US20050202053 Taste masking complex of antihistamine and alginate
09/15/2005US20050202044 A fusion protein containing an antigen of an influenza virus and a bacterial stress protein; vaccines induce a cytolytic T-cell (CTL) response in a mammal
09/15/2005US20050202033 Heat shock protein-based vaccines and immunotherapies
09/15/2005US20050202003 Methods for sterilizing preparations of monoclonal immunoglobulins
09/15/2005US20050201986 Cell targeting compositions and methods of using the same
09/15/2005US20050201973 Therapeutic supramolecules
09/15/2005US20050201950 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
09/15/2005US20050201948 Granules of sugar such as glucose, lactose, fructose, mannitol or sucrose; dry powder inhalers
09/15/2005US20050201946 Intranasal influenza virus vaccine
09/15/2005US20050201942 Preparing microbubble-generating carbohydrate microparticles with an incorporated surfactant by freeze drying; enhanced echocardiographic imaging
09/15/2005US20050201941 Magnetic nanoparticle
09/15/2005US20050201940 Diagnostics and radiotherapy; magnetic resonance imaging (MRI); treatment of a tumor
09/15/2005US20050201934 Binding peptides for carcinoembryonic antigen (CEA)
09/15/2005US20050201932 Drug delivery using Polymeric immunoglobulin receptor (pIgR) which when cleaved has a stalk region which remains attached to the cell and a secretory component (SC) which exists in an organ of interest in several forms
09/15/2005US20050201930 Ultrasonic contrast agents; aqueous suspension
09/15/2005US20050201888 Sterilization process
09/15/2005DE102004009783A1 Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen Hyperbranched starch fraction, processes for their preparation and their conjugates with active pharmaceutical ingredients
09/15/2005CA2559188A1 Hyaluronic acid-methotrexate conjugate
09/15/2005CA2558416A1 Use of lipid conjugates in the treatment of disease
09/15/2005CA2558399A1 Partially loaded antibodies and methods of their conjugation
09/15/2005CA2558379A1 Multi-component biological transport systems
09/15/2005CA2557968A1 Method and composition for burned skin
09/15/2005CA2557876A1 Powdered compositions of sensitive active materials in an at least partially amorphous state
09/15/2005CA2557634A1 Stable capsule preparation
09/15/2005CA2556790A1 Enzyme-prodrug therapy for prosthetic joint repair
09/15/2005CA2555612A1 Compositions and methods for the treatment and clinical remission of psoriasis
09/14/2005EP1574578A1 Monomeric protein of the TGF-beta family
09/14/2005EP1574577A2 Growth differentiation factor-11
09/14/2005EP1574222A1 Sterilization process
09/14/2005EP1574221A1 Stable injectable diclofenac compositions
09/14/2005EP1574217A1 Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants
09/14/2005EP1574215A1 Solid drug for oral use
09/14/2005EP1574214A1 Pharmaceutical composition comprising fenofibrate and process for its preparation
09/14/2005EP1574207A1 Cosmetic use of viscous compositions containing carbon dioxide
09/14/2005EP1574201A1 Composition of an external dermatological agent
09/14/2005EP1573024A2 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
09/14/2005EP1573023A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
09/14/2005EP1573022A2 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
09/14/2005EP1573003A2 Method for producing transgenic animals using oral gene therapy
09/14/2005EP1572963A2 Carbohydrate-based synthetic vaccines for hiv
09/14/2005EP1572930A2 Albumin-fused kunitz domain peptides
09/14/2005EP1572918A2 Synthetic glyco-lipo-peptides as vaccines
09/14/2005EP1572908A2 Chimeric molecules for cleavage in a treated host
09/14/2005EP1572747A2 Tumor-specific recognition molecules
09/14/2005EP1572728A2 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
09/14/2005EP1572719A2 Partial peptide mimetics and methods
09/14/2005EP1572676A2 High specificity anticancer pharmacological drug system, drug synthesis, and drug development process
09/14/2005EP1572665A2 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors
09/14/2005EP1572639A1 Integrin targeted imaging agents
09/14/2005EP1572244A1 Oral formulations for poorly absorptive hydrophilic drugs
09/14/2005EP1572243A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent
09/14/2005EP1572242A1 Immunoconjugates with an intracellularly-cleavable linkage
09/14/2005EP1572241A1 Oral pharmaceutical compositions comprising cyclosporin
1 ... 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 ... 1712